A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Study of Emricasan in subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Sponsor: Conatus Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5409
U.S. Govt. ID: NCT03205345
Contact: Cristina Falo PhD: 1 212 305 6758 / cf2427@cumc.columbia.edu
Additional Study Information: Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and efficacy of a drug called Emricasan (IDN-6556) in reducing the risk of complications related to liver disease. Eligible patients will be randomized to receive 5 mg or 25 mg of emricasan, or placebo orally twice a day for at least 48 weeks (and potentially up to 2.5 years, depending on enrollment timeline).
This study is closed
Elizabeth Verna, MD
Do You Qualify?
Have you been diagnosed with cirrhosis? Yes No
Have you been diagnosed with NASH or fatty liver disease? Yes No
Have you had a liver transplant? Yes No
Have you had cancer of the liver? Yes No
Do you have HIV? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Cristina Falo PhD
1 212 305 6758